To examine the renal CTC-capture efficiency of using CA9 and CD147 as capture antigens, we first used the NanoVelcro platform to capture renal cancer cells from two representative human CCRCC lines, Caki-1 and Caki-2. This evidence concerns the gene CA9 and renal carcinoma.